Hansoh's Olatorepatide Achieved 19.3% Weight Loss in Phase III Study
Hansoh Pharma presented Phase III trial results for olatorepatide, a weight management drug candidate. The study showed significant weight loss and favorable tolerability in Chinese adults with overweight or obesity.
Milan – Hansoh Pharma presented findings from its Phase III LIGHTEN study of olatorepatide (HS-20094) at the European Association for the Study of Diabetes (EASD) annual meeting. Olatorepatide is a dual GLP-1/GIP receptor agonist developed by Hansoh for weight management.
The study demonstrated that participants receiving the 15 mg dose of olatorepatide achieved an average weight loss of 19.3% at 48 weeks, with no plateau observed. Waist circumference decreased by an average of 16.0 cm. Gastrointestinal adverse events, such as nausea (7.8%) and vomiting (4.9%), were reported at low rates. The trial enrolled 604 overweight or obese Chinese adults.
The LIGHTEN trial was a multicenter, randomized, double-blind, placebo-controlled study. Participants received subcutaneous injections of 5 mg, 10 mg, or 15 mg of olatorepatide, or placebo, once weekly for 48 weeks. All doses of olatorepatide showed statistically significant greater weight loss compared to placebo. The weight loss trend continued beyond 48 weeks, suggesting potential for further weight reduction with longer treatment durations.
Olatorepatide also improved metabolic parameters including blood pressure, lipid profile, and glycosylated hemoglobin (HbA1c). The drug's safety profile was comparable to other approved incretin-based therapies for weight management, with lower gastrointestinal side effects than previously reported for the drug class. Hansoh Pharma is also developing olatorepatide for type 2 diabetes in China.